Antipsoriatic and proinflammatory action of anthralin: Implications for the role of oxygen radicals

Biochemical Pharmacology

Volumn 53, Issue 9, 1997, Pages 1215-1221

  Müller, Klaus ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Anthralin; Antiproliferative action; Dithranol; Free radicals; Oxygen radicals; Psoriasis; Skin inflammation

Indexed keywords

DITHRANOL;

ANTIINFLAMMATORY ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PSORIASIS; REVIEW; SKIN INFLAMMATION;

EID: 18344412314     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00732-0     Document Type: Note

References (69)

1. Camisa C, Psoriasis. Blackwell Scientific Publishers, Oxford, 1994.
2. Kemény L, Ruzicka T and Braun-Falco O, Dithranol: A review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol 3: 1-20, 1990.
3. Wiegrebe W and Müller K, Treatment of psoriasis with anthrones - Chemical principles, biochemical aspects, and approaches to the design of novel derivatives. Skin Pharmacol 8: 1-24, 1995.
4. Cavey D, Caron J-C and Shroot B, Anthralin: Chemical instability and glucose-6-phosphate dehydrogenase inhibition. J Pharm Sci 71: 980-983, 1982.
5. Müller K, Antipsoriatic anthrones: Aspects of oxygen radical formation, challenges and prospects. Gen Pharmacol (in press).
6. Halliwell B and Gutteridge JMC, Role of free radicals and catalytic metal ions in human disease: An overview. Methods Enzymol 186: 1-85, 1990.
7. Gutteridge JMC, Free radicals in disease processes: A compilation of cause and consequence. Free Radic Res Commun 19: 141-158, 1993.
8. Rice-Evans C, Free radicals and antioxidants in normal and pathological processes. In: Oxidative Stress, Lipoproteins and Cardiovascular Dysfunction (Eds. Rice-Evans C and Bruckdorfer KR), pp. 1-32. Portland Press, London, 1995.
9. Martinmaa J, Vanhala L and Mustakallio KK, Free radical intermediates produced by autoxidation of 1,8-dihydroxy-9-anthrone (dithranol) in pyridine. Experientia 34: 872-873, 1978.
10. Davies AG, Hawari JA-A and Whitefield M, Generation and ESR spectrum of the 1,8-dihydroxy-9-anthrone-10-yl-radical. Tetrahedron Lett 24: 4465-4468, 1983.
11. Shroot B and Brown C, Free radicals in skin exposed to dithranol and its derivatives. Arzneimittelforschung 36: 1253-1255, 1986.
12. Fuchs J and Packer L, Investigations on anthralin free radicals in model systems and in skin of hairless mice. J Invest Dermatol 92: 677-682, 1989.
13. Mäder K, Bacic G and Swartz M, In vivo detection of anthralin-derived free radicals in the skin of hairless mice by low-frequency electron paramagnetic resonance spectroscopy. J Invest Dermatol 104: 514-517, 1995.
14. Lambelet P, Löliger J and Shroot B, Role of free radicals in the mode of action of anthralin. Skin Pharmacol 1: 115-121, 1988.
15. Finnen MJ, Lawrence CM and Shuster S, Inhibition of dithranol inflammation by free-radical scavengers. Lancet II: 1129-1130, 1984.
16. Bruce JM, Dodd NFJ, Gorman AA, Hamblett I, Kerr CW, Lambert C and McNeeney SP, Anthralin-derived transients - II. Formation of the radical by spontaneous fragmentation of both singlet and triplet states of the 10,10′-dehydrodimer: Radical pair multiplicity effects. Photochem Photobiol 52: 345-352, 1990.
17. Hayden PJ and Chignell CF, Detection and characterization of 9-anthron-10-yl radicals formed by antipsoriatic and tumor-promoting 9-anthrones in aqueous buffers. Chem Res Toxicol 6: 231-237, 1993.
18. Müller K, Wiegrebe W and Younes M, Formation of active oxygen species by dithranol, III. Dithranol, active oxygen species and lipid peroxidation in vivo. Arch Pharm (Weinheim) 320: 59-66, 1987.
19. Bruce JM, Kerr CW and Dodd NJF, Formation of superoxide during the auto-oxidation of anthralin (1,8-dihydroxy-9-anthrone). J Chem Soc Faraday Trans I 83: 85-89, 1987.
20. Miller DM, Buettner GR and Aust SD, Transition metals as catalysts of "autoxidation" reactions. Free Radic Biol Med 8: 95-108, 1990.
21. Halmekoski J, Vilvala R and Mustakallio KK, Polarographic studies on dithranol and its 10-acyl analogs. In: Psoriasis (Eds. Farber EM, Cox AJ, Nall L and Jacobs PH), pp. 381-382. Grune & Stratton, New York, 1982.
22. Halliwell B, How to characterize a biological antioxidant. Free Radic Res Commun 9: 1-32, 1990.
23. Müller K and Kappus H, Hydroxyl radical formation by dithranol. Biochem Pharmacol 37: 4277-4280, 1988.
24. Müller K and Gürster D, Hydroxyl radical damage to DNA sugar and model membranes induced by anthralin (dithranol). Biochem Pharmacol 46: 1695-1704, 1993.
25. Hayden PJ, Free KE and Chignell CF, Structure-activity relationships for the formation of secondary radicals and inhibition of keratinocyte proliferation by 9-anthrones. Mol Pharmacol 46: 186-198, 1994.
26. Müller K, Eibler E, Mayer KK, Wiegrebe W and Klug G, Dithranol, singlet oxygen and unsaturated fatty acids. Arch Pharm (Weinheim) 319: 2-9, 1986.
27. Dabestani R, Hall RD, Sik RH and Chignell CF, Spectroscopic studies of cutaneous photosensitizing agents - XV. Anthralin and its oxidation product, 1,8-dihydroxyanthraquinone. Photochem Photobiol 52: 961-971, 1990.
28. Müller K, Kanner RC and Foote CS, Kinetic studies on anthralin photooxidation. Photochem Photobiol 52: 445-450, 1990.
29. Halliwell B, Antioxidant characterization. Methodology and mechanism. Biochem Pharmacol 49: 1341-1348, 1995.
30. Schallreuter KU and Wood JM, Free radical reduction in the human epidermis. Free Radic Biol Med 6: 519-532, 1989.
31. Trenam CW, Blake DR and Morris CJ, Skin inflammation: Reactive oxygen species and the role of iron. J Invest Dermatol 99: 675-682, 1992.
32. Darr D and Fridovich I, Free radicals in cutaneous biology. J Invest Dermatol 102: 671-675, 1994.
33. Dogan P, Soyuer Ü and Tanrikulu G, Superoxide dismutase and myeloperoxidase activity in polymorphonuclear leukocytes, and serum ceruloplasmin and copper levels, in psoriasis. Br J Dermatol 120: 239-244, 1989.
34. Kobayashi T, Matsumoto M, Iizuka H and Taniguchi N, Superoxide dismutase in psoriasis, squamous cell carcinoma and basal cell epithelioma: An immunohistochemical study. Br J Dermatol 124: 555-559, 1991.
35. Müller K and Gawlik I, Inactivation of mouse epidermal 12-lipoxygenase by anthralin - implications for a role of oxygen radicals. Biochem Pharmacol 51: 1173-1179, 1996.
36. Anderson R, Dithranol-mediated, dose-dependent priming and activation of luminol-enhanced chemiluminescence response of human neutrophils in vitro. Br J Dermatol 121: 1-9, 1989.
37. Raab WP, Ingram method: the precursor of photochemotherapy. Br J Dermatol 105 (Suppl 20): 77-81, 1981.
38. Paramsothy Y and Lawrence CM, Time course and intensity of anthralin inflammation on involved and uninvolved psoriatic skin. Br J Dermatol 116: 517-519, 1987.
39. Schallreuter KU and Pittelkow MR, Anthralin inhibits elevated levels of thioredoxin reductase in psoriasis. Arch Dermatol 123: 1494-1498, 1987.
40. Trush MA, Mimnaugh EG and Gram TE, Activation of pharmacological agents to radical intermediates. Implications for the role of free radicals in drug action and toxicity. Biochem Pharmacol 31: 3335-3346, 1982.
41. Hsieh GC and Acosta D, Dithranol-induced cytotoxicity in primary cultures of rat epidermal keratinocytes. I. The role of reactive oxygen species. Toxicol Appl Pharmacol 107: 16-26, 1991.
42. Sies H, Biochemistry of oxidative stress. Angew Chem Int Edn Engl 25: 1058-1071, 1986.
43. Halliwell B and Aruoma OI, DNA damage by oxygen-derived species. Its mechanism and measurement in mammalian systems. FEBS Lett 281: 9-19, 1991.
44. Breen AP and Murphy JA, Reactions of oxyl radicals with DNA. Free Radic Biol Med 18: 1033-1077, 1995.
45. Müller K, Leukel P, Mayer KK and Wiegrebe W, Modification of DNA bases by anthralin and related compounds. Biochem Pharmacol 49: 1607-1613, 1995.
46. Birnboim HC, DNA strand breaks in human leukocytes induced by superoxide anion, hydrogen peroxide and tumor promoters are repaired slowly compared to breaks induced by ionizing radiation. Carcinogenesis 7: 1511-1517, 1986.
47. Clark JM and Hanawalt PC, Inhibition of DNA replication and repair by anthralin or danthron in cultured human cells. J Invest Dermatol 79: 18-22, 1982.
48. Forrester DMT, Van Rensburg CEJ and Anderson R, Prooxidative interactions of dithranol with human phagocytes promote oxidative damage to DNA of bystander leukocyte. Mutat Res 247: 39-44, 1991.
49. Halliwell B and Gutteridge JMC, Free Radicals in Biology and Medicine, 2nd Edn. Clarendon Press, Oxford, 1989.
50. Girotti AW, Photodynamic lipid peroxidation in biological systems. Photochem Photobiol 51: 497-509, 1990.
51. Bindoli A, Lipid peroxidation in mitochondria. Free Radic Biol Med 5: 247-261, 1988.
52. Fuchs J, Milbradt R and Zimmer G, Multifunctional analysis of the interaction of anthralin and its metabolites anthraquinone and anthralin dimer with the inner mitochondrial membrane. Arch Dermatol Res 282: 47-55, 1990.
53. Kohen E, Kohen C, Morlière P, Santus R, Reyftmann JP, Dubertret L, Hirschberg JG and Coulomb B, A microspectrofluorometric study of the effect of anthralin, an antipsoriatic drug, on cellular structures and metabolism. Cell Biochem Funct 4: 157-168, 1986.
54. Fuchs J, Nitschmann WH and Packer L, The antipsoriatic compound anthralin influences bioenergetic parameters and redox properties of energy transducing membranes. J Invest Dermatol 94: 71-76, 1990.
55. Stadtman ER, Metal ion-catalyzed oxidation of proteins: Biochemical mechanism and biological consequences. Free Radic Biol Med 9: 315-325, 1990.
56. Davies KJA, Delsignore ME and Lin SW, Protein damage and degradation by oxygen radicals. II. Modification of amino acids. J Biol Chem 262: 9902-9907, 1987.
57. Bedord CJ, Young JM and Wagner BM, Anthralin inhibition of mouse epidermal arachidonic acid lipoxygenase in vitro. J Invest Dermatol 81: 566-571, 1983.
58. Müller K and Gawlik I, Novel 10-substituted antipsoriatic anthrones as inhibitors of epidermal 12-lipoxygenase and lipid peroxidation in membranes. Biochem Pharmacol 50: 2077-2083, 1995.
59. Kemal C, Louis-Flamberg P, Krupinski-Olsen R and Shorter AL, Reductive inactivation of soybean lipoxygenase 1 by catechols: A possible mechanism for regulation of lipoxygenase activity. Biochemistry 26: 7064-7072, 1987.
60. Halliwell B and Gutteridge JMC, Role of iron in oxygen radical reactions. Methods Enzymol 105: 47-56, 1984.
61. Schmidt KN, Podda M, Packer L and Baeuerle PA, Antipsoriatic drug anthralin activates transcription factor NF-κB in murine keratinocytes. J Immunol 156: 4514-4519, 1996.
62. Schulze-Osthoff K, Los M and Baeuerle PA, Redox signalling by transcription factors NF-κB and AP-1 in lymphocytes. Biochem Pharmacol 50: 735-741, 1995.
63. Viluksela M, Characteristics and modulation of dithranol (anthralin)-induced skin irritation in the mouse ear model. Arch Dermatol Res 283: 262-268, 1991.
64. Kemény E, Csato M and Dobozy A, Pharmacological studies on dithranol-induced irritative dermatitis in mice. Arch Dermatol Res 281: 362-365, 1989.
65. Fuchs J and Milbradt R, Antioxidant inhibition of skin inflammation induced by reactive oxidants: Evaluation of the redox couple dihydrolipoate/lipoate. Skin Pharmacol 7: 278-284, 1994.
66. Farber EM and Nall L, Psoriasis. A review of recent advances in treatment. Drugs 28: 324-346, 1984.
67. Müller K, Gürster D, Piwek S and Wiegrebe W, Antipsoriatic anthrones with modulated redox properties. 1. Novel 10-substituted 1,8-dihydroxy-9(10H)-anthracenones as inhibitors of 5-lipoxygenase. J Med Chem 36: 4099-4107, 1993.
68. Müller K, Huang H-S and Wiegrebe W, Antipsoriatic anthrones with modulated redox properties. 3. 10-Thiosubstituted 1,8-dihydroxy-9(10H)-anthracenones as inhibitors of keratinocyte growth, 5-lipoxygenase, and the formation of 12(S)-HETE in mouse epidermis. J Med Chem 39: 3132-3138, 1996.
69. Müller K, Leukel P, Ziereis K and Gawlik I, Antipsoriatic anthrones with modulated redox properties. 2. Novel derivatives of chrysarobin and isochrysarobin - Antiproliferative activity and 5-lipoxygenase inhibition. J Med Chem 37: 1660-1669, 1994.